Erschienen in:
01.12.2013 | Gastrointestinal Oncology
Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Asian Perspective
verfasst von:
Winson Jianhong Tan, MBBS(Hons), MRCS, MMed, Joelle Fui Sze Wong, MBBS, MRCS, Claramae Shulyn Chia, MBBS, MRCS, MMed, FRCS, Grace Hwee Ching Tan, MBBS, MRCS, Khee Chee Soo, MBBS, MD, FRACS, FACS, Melissa Ching Ching Teo, MBBS, FAMS, FRCS, MPH
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 13/2013
Einloggen, um Zugang zu erhalten
Abstract
Background
Data on quality of life (QOL) after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) is scarce in the Asian population. This study assesses QOL outcomes after CRS and HIPEC in an Asian cancer center.
Methods
Patients who completed CRS + HIPEC 6–18 months ago (27 patients) were enrolled in the study. QOL was measured via the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaires. The scores were compared with a group of 393 disease-free cancer patients, not on active treatment, who had ECOG scores of either 0 or 1. The 1-sample t test was used to compare differences in QOL scores between the 2 groups.
Results
A total of 27 patients were analyzed, of which 22 (81 %) were females. Median age was 51 years (15–59 years). CRS + HIPEC were performed for ovarian cancer in 15 patients (55 %), appendiceal carcinoma in 5 patients (19 %), and colorectal carcinoma in 4 patients (15 %). The median intraoperative peritoneal carcinomatosis index (PCI) score was 15 (2–31) while the completeness of CC score was 0 and 1 in 25 and 2 patients, respectively. The median duration after CRS + HIPEC was 10 months (6–16 months). Global health status and functional and symptom scores were largely similar between patients after CRS + HIPEC and the control group. Cognitive functioning scores and fatigue scores were significantly better in the group after CRS + HIPEC (p = 0.014 and 0.04).
Conclusions
QOL after CRS and HIPEC can be equivalent to that of well-functioning, disease-free cancer patients.